| OMC |
Report |
Core Organic Revenue Growth (Q2 2026) |
BEAT |
pred ~4.2% vs. cons 3.63% |
MEDIUM |
| OMC |
Report |
Diluted Operating EPS (Q2 2026) |
BEAT |
pred ~$2.68 vs. cons $2.61 |
MEDIUM |
| OMC |
Report |
EBITDA - Operating (Q2 2026) |
BEAT |
pred ~$1.24B vs. cons $1.21B |
MEDIUM |
| OMC |
Guide |
Organic Growth (FY 2026) |
BETTER |
guide ~4% maintained vs. cons 3.73% |
HIGH |
| OMC |
Guide |
Diluted Operating EPS (FY 2026) |
UNCHANGED |
guide 'higher double digits' maintained vs. cons $10.77 |
MEDIUM |
| OMC |
Guide |
Synergy Realization (FY 2026) |
UNCHANGED |
$900M on track, maintained vs. consensus |
HIGH |
| OMC |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
MEDIUM |
| OMC |
Return |
5-day cumulative residual |
-2.0% (STABILIZE) |
STABILIZE — modest upward organic revision offsets no-formal-raise disappointment; short covering provides a floor |
MEDIUM |